We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Custom Monoclonal Antibody Reveals Promising HER2+ Breast Cancer Target

Immunohistochemistry on a human breast cancer tissue microarray.
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

AMSBIO has supplied a custom monoclonal antibody (mAB) to researchers at the TU Dortmund** in Germany to unravel the role of EDI3 in breast cancer development, its regulation by HER2 signalling, and its potential as a therapeutic target.

Characterized by the overexpression of the Human Epidermal growth factor Receptor 2 (HER2) - HER2+ breast cancer is a highly aggressive disease subtype. While HER2-targeted treatments have improved patient outcomes for this form of cancer, acquired and inherent resistance to these treatment remains a challenge, prompting investigations into alternative therapeutic targets.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

The team of researchers, led by Dr. Rosemarie Marchan, has conducted an extensive study to explore the clinical relevance of EDI3 - a glycerophosphodiesterase enzyme involved in choline metabolism, in HER2-positive breast cancer using the custom mAB against EID3 prepared and supplied by AMSBIO.

Dr Marchan commented “We have tested many off-the-shelf antibodies over the years, with little to no success. We have also contracted companies to create a custom antibody for us, but again with limited success. Therefore, we are very thankful a few years ago that we were able to get a great antibody against EID3 from AMSBIO. Using this precious antibody our team has been able to demonstrate that inhibiting EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth”.